Sanofi Shares Rebound in Late Afternoon Following Target Revision
Sanofi shares increased by 1.66% this Friday, January 30, 2026, in the late afternoon, reaching 78.36 euros. This rebound follows the publication of solid annual results and several adjustments in analysts' recommendations. However, over the year, the stock has declined by 23.07%, reflecting a challenging stock market environment for the laboratory.
Analysts Revise Expectations on Sanofi Stock
Analysts have recently revised their expectations on the stock, with significantly lowered price targets. Citigroup set a target at 85 euros on January 27, accompanied by a neutral opinion on the stock. Meanwhile, UBS lowered its target from 105 euros to 88 euros on January 16, also with a neutral recommendation. These adjustments reflect increased caution from investment banks, although the targets show a potential upside of between 8.5% and 12.3% compared to the current price.
These revisions come after the publication of the group's robust annual results, which confirmed an acceleration of growth in the fourth quarter of 2025. Dupixent, the laboratory's flagship drug, and new treatments have driven commercial momentum, while operational discipline has strengthened profitability. For 2026, the pharmaceutical group anticipates the continuation of a profitable trajectory, supported by its development pipeline and targeted capital allocation.
Technical Analysis of Sanofi Stock
From a graphical perspective, Sanofi is still trading below the 20-day moving average located at 80.62 euros. The 50-day average is positioned at 82.68 euros, while the 200-day average is established at 85.04 euros, illustrating a persistent downward trend. The RSI is at a level of 27, indicative of an oversold zone, which suggests a technical potential for a short-term recovery.
The stock crossed its support threshold at 77.08 euros during the session, while a major resistance remains at 84.44 euros. The one-month volatility reaches 6.81%, reflecting sustained price movements amid ongoing uncertainties over pharmaceutical sector valuations. Crossing the support could nevertheless initiate a stabilization phase if the current rebound confirms in the upcoming sessions.
